MALIGNANT SOLID TUMOR

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can sh…

This study tests whether a single injection of Telpegfilgrastim works better than daily Filgrastim shots to prevent fever and low white blood cells in children and young adults (ages 6-24) with solid tumors receiving strong chemotherapy. About 132 participants will receive either…

This study tests targeted cancer drugs in people with advanced solid tumors that have not responded to standard treatments. Participants receive a drug chosen based on the genetic changes in their tumor. The goal is to see if the treatment can stop or shrink the cancer for at lea…

This study tests whether a structured nutrition program can prevent malnutrition in children with solid tumors. About 400 children will receive a team-based nutrition plan including special diets. The goal is to improve weight, height, and overall health during treatment.

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This early-stage study tests a personalized mRNA vaccine (RGL-270) in people with solid tumors who have a high chance of the cancer returning after standard treatment. The vaccine is designed to train the immune system to recognize and attack leftover cancer cells. Some participa…

This study tests an experimental drug called FH-006 in 200 people with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive FH-006 by IV every 2 or 3…

This early-phase trial is testing a new imaging agent (GEH200520/GEH200521) that lights up on PET scans to help see solid tumors. In Part A, 50 adults with advanced solid tumors will receive the agent and have scans to check safety and how the agent spreads in the body. Part B wi…

This study tests whether a combination of two drugs (fosrolapitant and palonosetron) can prevent nausea and vomiting in people receiving strong chemotherapy for the first time. About 200 adults with solid tumors will be enrolled. The goal is to see if this treatment helps patient…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This study is collecting information from 5,500 Canadian cancer patients whose tumors have rare genetic changes. Researchers want to see how well current targeted drugs work for these uncommon mutations. Participants are observed over time, and their treatment outcomes, side effe…